MedCity News August 30, 2024
Frank Vinluan

Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic.

As an mpox outbreak in Africa continues to spread, the FDA has approved an Emergent BioSolutions vaccine for preventing infection from this pathogen. The regulatory decision could be the first of several for this vaccine, which is also being discussed with health authorities around the world.

The vaccine, ACAM2000, was initially developed to protect against smallpox. Mpox is a member of the same family of viruses as smallpox. Using a live version of vaccinia, a virus that is related to smallpox but causes milder disease, ACAM2000 is intended to spark the immune system to produce...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID
Related Articles:
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
Trump's FDA Pick Is MedPage Today's Former Top Editor

Share This Article